Today’s Shorts Alert: GLOBEIMMUNE INCORPORATED (GBIM) on Focus After Interesting Change

November 25, 2016 - By Ellis Scott

Today's Shorts Alert: GLOBEIMMUNE INCORPORATED (GBIM) on Focus After Interesting Change

Interested investors have been looking for information on shares of GLOBEIMMUNE INCORPORATED (OTCMKTS:GBIM) after the stock moved $0.01, hitting the $0.55 price point in a recent trade.

It’s the latest price, but let’s analyze how the stock has been doing recently. In the past year, GLOBEIMMUNE INCORPORATED’s stock was big mover. According to the short interest report published recently, (GBIM) had 18,800 shorted shares for 0.3 days to cover. The prior short interest was 28,500 for a $-34.04 change. The 52-Week High and Low are noted here. -91.27% (High), 57.14%, (Low). The stock had 57,800 average volume.

Enroll for Our Newsletter Today and know if shares price of GLOBEIMMUNE INCORPORATED (OTCMKTS:GBIM) is Ready to Breakout!

Penny stocks are often stated as risky investments that hardly pay off. Admittedly, there is fact to this, but with the right knowledge and tactics, it is possible to earn a significant amount of gain in penny stocks. Simply said, a penny stock is an equity that trades at a low price.

Irrespective of the name, penny stocks usually are priced over a penny, occupying a price range at or close to $1, though some are priced a fraction of a penny. Often referred to as micro-cap equities, the Securities & Exchange Commission classifies these types of securities as being $5 or less. Over-the-counter stocks are NOT listed on any of the formal exchanges.

So, penny stocks frequently fit in this segment, though many dodge this category. Over-the-counter (OTC) equities are stated to be risky as they aren’t contingent to the listing and reporting requirements of the reputed commodity exchanges.

Register in the Bar Below to Obtain Breaking Alerts on Shares That Are Set to Make a Move!

Penny shares can be listed on NASDAQ or other known stock exchanges, although many more cannot be found there. A major percentage of penny stocks are listed on the so-named ‘pink sheets’, i.e., daily news of OTC shares. They can even be seen on the ‘Over-the-Counter Bulletin Board.’ Commodities listed on the OTCBB fail to fulfill the listing guidelines of the NYSE or other known exchanges, although they are mandated to file financial statements with known regulators, such as the SEC. Penny shares are inexpensive, thus attractive to shareholders who lack the funds to buy comparatively expensive blue-chip stocks from large firms.

Penny stocks boast immense profit potential. Because these stocks trade cheap, even a slight jump in price turns to be profitable. Look out, however, because frequently shareholders may have trouble getting a decent amount of details about penny stocks. These kinds of shares tend to be latest in news, with almost no track record for investors research.

In addition, penny stocks show lack of market activity, with poor liquidity, making them difficult to sell. Poor liquidity results in penny stocks to be open to price influence.

A shady trader can simply buy large sums of shares, temporarily leading up the price, crafting artificial demand.

Disclaimer: Nothing mentioned in this publication is planned to constitute legal, securities, tax, or investment advice, nor a viewpoint regarding the relevance of any investment, nor any type of solicitation. The general information mentioned in this article should not be acted upon without getting specific tax, legal and investment advice from a certified professional.

More recent GlobeImmune Inc (OTCMKTS:GBIM) news were published by: Quotes.Wsj.com which released: “GlobeImmune Inc. GBIM (US: OTC)” on September 15, 2012. Also Denverpost.com published the news titled: “With half-dozen employees, GlobeImmune weighs sale” on August 14, 2015. Fiercebiotech.com‘s news article titled: “GlobeImmune, Inc. Reports Positive Results for Two Therapeutic Vaccines, GI …” with publication date: June 01, 2011 was also an interesting one.

GlobeImmune, Inc. is a biopharmaceutical company. The company has a market cap of $2.70 million. The Firm is focused on developing products for the treatment of cancer and infectious diseases based on its Tarmogen platform. It currently has negative earnings. The Company’s segment is the business of developing and commercializing various biopharmaceutical products.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>